Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis b patients: A pilot randomized controlled study

Jun Inoue, Takehiro Akahane, Tomoo Kobayashi, Noriyuki Obara, Teruyuki Umetsu, Eiji Kakazu, Masashi Ninomiya, Tomoaki Iwata, Akitoshi Sano, Mio Tsuruoka, Kosuke Sato, Atsushi Masamune

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Although hepatitis B surface antigen (HBsAg) removal is considered the goal of chronic hepatitis B treatment, it can rarely be achieved with nucleos(t)ide analogues (NAs). It has been reported that tenofovir disoproxil fumarate (TDF) is superior in reducing HBsAg compared with entecavir (ETV) in treatment-naïve patients; however, the effect of TDF in patients who have received NAs is still unclear. The aim of the present study was to evaluate the efficacy of switching from ETV to TDF in patients who were already receiving ETV. A pilot randomized controlled study for 2 years in patients who had been treated with ETV for >1 year and did not exhibit drug resistance was performed (Clinical trial registration: UMIN000021948, UMIN-CTR, May 1, 2016). A total of 20 patients were enrolled and 19 patients were randomized into 2 groups, a TDF-switching group (n=12) or an ETV-continuing group (n=7). The mean change in HBsAg levels after 2 years was greater in the TDF group compared with the ETV group, but the difference was not significant (-0.25 vs. -0.06 log IU/ml). In the TDF group, hepatitis B e antigen (HBeAg)-positive patients at baseline showed significantly greater changes in HBsAg (-0.63 vs. -0.03 log IU/ml; P=0.030). In contrast, no difference between HBeAg-positive and HBeAg-negative patients was observed in the ETV group. No significant differences of estimated glomerular filtration rate and inorganic phosphorus changes were observed among the TDF and ETV groups. In conclusion, a significant HBsAg decrease was not achieved after switching from ETV to TDF in the overall analysis, but HBeAg-positive patients showed a larger HBsAg decrease after switching treatment.

Original languageEnglish
Article number20
Pages (from-to)1-6
Number of pages6
JournalBiomedical Reports
Issue number2
Publication statusPublished - 2020 Feb


  • Entecavir
  • Hepatitis B e antigen
  • Hepatitis B surface antigen
  • Hepatitis B virus
  • Tenofovir disoproxil fumarate


Dive into the research topics of 'Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis b patients: A pilot randomized controlled study'. Together they form a unique fingerprint.

Cite this